T73334 |
Larotinib
|
1438072-11-7
|
98.45%
|
|
Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.
|
TQ0255 |
Olafertinib
|
1660963-42-7
|
98.43%
|
|
Olafertinib (RX-518) is a novel mutant-selective, irreversible, orally available EGFR inhibitor. It can overcome T790M-mediated resistance in NSCLC.
|
T14138 |
AG-825
|
149092-50-2
|
98.43%
|
|
AG-825(Tyrphostin C15) is a selective and competitive ErbB2 inhibitor that inhibits tyrosine phosphorylation with an IC50 value of 0.35 μM.AG-825 (Tyrphostin C15...
|
T3545 |
RG13022
|
136831-48-6
|
98.38%
|
|
RG13022 (Tyrphostin RG13022) is a tyrosine kinase inhibitor; inhibits the autophosphorylation reaction of the EGF receptor (IC50: 4 μM).
|
T2327 |
Pelitinib
|
257933-82-7
|
98.37%
|
|
Pelitinib (EKB-569) (EKB-569) is an effective irreversible EGFR inhibitor (IC50: 38.5 nM).
|
T6092 |
Sapitinib
|
848942-61-0
|
98.35%
|
|
Sapitinib (AZD-8931) , a reversible, ATP competitive inhibitor of EGFR(IC50=4 nM), ErbB2(IC50=3 nM) and ErbB3(IC50=4 nM), is more effective over Gefitinib or Lap...
|
T11569 |
HKI-357
|
848133-17-5
|
98.31%
|
|
HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 (IC50s: 34 nM and 33 nM). HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK ph...
|
T10965 |
DBPR112
|
1226549-49-0
|
98.29%
|
|
DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC50s of 15 nM and 48 nM for EGFRWT and EGFRL858R/T790M, respectively. DBPR112 can occupy ...
|
T30855 |
CGP77675
|
234772-64-6
|
98.23%
|
|
CGP77675 (ZINC1488120) is a potent and selective inhibitor of Src family kinase with IC50s of 5-20 and 40 nM for the phosphorylation of peptide substrates and au...
|
T1737 |
Genistein
|
446-72-0
|
98.22%
|
|
Genistein (NPI 031L) is an isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA TOPOISOMERASES, TYPE II), with a...
|
T2518 |
ARRY-380 (analog )
|
937265-83-3
|
98.22%
|
|
ARRY-380 analog (HER2-Inhibitor-1) is a potent and selective HER2 inhibitor.
|
T4183 |
Lavendustin A
|
125697-92-9
|
98.17%
|
|
lavendustin A (RG-14355) is a potent, cell-permeable inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase.
|
TN1440 |
Beta-Hydroxyisovalerylshikonin
|
7415-78-3
|
98.16%
|
|
Beta-Hydroxyisovalerylshikonin is an inhibitor of protein-tyrosine kinases such as v-Src and EGFR, and has been shown to induce apoptosis in several human tumor ...
|
T2642 |
PD173074
|
219580-11-7
|
98.15%
|
|
PD173074 is an effective FGFR1 inhibitor (IC50: 25 nM) and also inhibits VEGFR2 (IC50: 100-200 nM) in cell-free assays. The selectivity is higher ~1000-fold for ...
|
T12777 |
RTC-5
|
1423077-49-9
|
98.14%
|
|
RTC-5 (TRC-382) (TRC-382) is a phenothiazine compound that has been specifically enhanced for its potent anti-cancer properties. It exhibits considerable effecti...
|
T6238 |
WZ4002
|
1213269-23-8
|
98.12%
|
|
WZ4002 is a mutant-selective EGFR inhibitor for EGFR(L858R) and EGFR(T790M) with IC50 of 2 nM/8 nM.
|
T17182 |
TX1-85-1
|
1603845-32-4
|
98.12%
|
|
TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling. TX1-85-1 is an irreversible Her3 inhibitor (IC50: 23 nM). TX1-85-1 ...
|
T64124 |
Sunvozertinib
|
2370013-12-8
|
98.11%
|
|
Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor and has inhibitory effects on EGFR, Her2 and mutant epidermal growth factor. Sunvozertinib showed inh...
|
T21954 |
EGFR/ErbB-2/ErbB-4 inhibitor-2
|
179248-61-4
|
98.1%
|
|
EGFR/ErbB-2/ErbB-4 inhibitor-2 (EGFR/ErbB2 Inhibitor) is a cell-permeable inhibitor of EGFR and c-ErbB2 (IC50s = 20 and 79 nM, respectively)
|
T19965 |
Dacomitinib hydrate
|
1042385-75-0
|
98.05%
|
|
Dacomitinib hydrate (PF 299804) is a highly selective and second-generation small-molecule inhibitor of the pan-epidermal growth factor receptor family of tyrosi...
|